🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this study is to determine the effect on toxicity of the add...
Status
Completed
Location
Zentrum fur Pneumologie und Thoraxchirurgie
Start Date
2009-06
Trial ID
NCT00991796
Treatments Being Tested
Breast cancer is the most commonly diagnosed cancer and the second leading ...
Status
Completed
Location
University of Alabama at Birmingham (UAB)
Start Date
2011-03
Trial ID
NCT01307891
Treatments Being Tested
The purpose of this study is to determine the safety and efficacy of CS-100...
Status
Completed
Location
Kenmar Research Group
Start Date
2010-07-09
Trial ID
NCT01033240
Treatments Being Tested
Treatment with CS-1008 in combination with FOLFIRI (irinotecan, leucovorin,...
Status
Completed
Location
Mayo Clinic
Start Date
2010-05
Trial ID
NCT01124630
Phase 2 study to determine the efficacy and safety of CS-1008 when given wi...
Status
Completed
Location
Multiple Locations
Start Date
2007-08-15
Trial ID
NCT00521404
Treatments Being Tested
This was a Phase 1, open-label, single-center study of CS-1008, an immunogl...
Status
Completed
Location
Ludwig Institute Tumor Targeting Program, Austin Health
Start Date
2010-10-12
Trial ID
NCT01220999
Treatments Being Tested
The purpose of this study is the use of buprenorphine/naloxone in treatment...
Status
Completed
Location
New York MDRU
Start Date
1996-04
Trial ID
NCT00015171
Treatments Being Tested
This trial assessed the effect of treatment with CS-1008 in combination wit...
Status
Completed
Location
Univ. Alabama
Start Date
2009-10-06
Trial ID
NCT00945191
Treatments Being Tested
The purpose of this study is to determine the effect of CS-1008 in combinat...
Status
Terminated
Location
Broomfield Hospital
Start Date
2009-07
Trial ID
NCT00969033
Treatments Being Tested
This is a dose escalation study of CS-1008 (humanized anti-DR5 antibody) to...
Status
Completed
Location
University of Alabama at Birmingham
Start Date
TBD
Trial ID
NCT00320827
Treatments Being Tested